Point72 Asset Management
ACRS icon

Point72 Asset Management’s Aclaris Therapeutics ACRS Stock Holding History

Point72 Asset Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-87,175
Closed -$262K – 3718
2025
Q4 		$262K Buy
+87,175
New +$220K ﹤0.01% 3530
2023
Q4 		– Sell
-662,529
Closed -$4.54M – 2095
2023
Q3 		$4.54M Sell
662,529
-1,073,971
-62% -$9.18M 0.01% 908
2023
Q2 		$18M Buy
1,736,500
+391,900
+29% +$3.55M 0.05% 413
2023
Q1 		$10.9M Sell
1,344,600
-438,000
-25% -$5.56M 0.03% 526
2022
Q4 		$28.1M Sell
1,782,600
-70,651
-4% -$1.14M 0.1% 263
2022
Q3 		$29.2M Buy
1,853,251
+119,351
+7% +$1.88M 0.12% 232
2022
Q2 		$24.2M Sell
1,733,900
-543,200
-24% -$7.61M 0.1% 269
2022
Q1 		$39.3M Buy
2,277,100
+1,634,200
+254% +$22.3M 0.16% 181
2021
Q4 		$9.35M Buy
642,900
+251,600
+64% +$3.81M 0.04% 529
2021
Q3 		$7.04M Sell
391,300
-87,300
-18% -$1.4M 0.03% 580
2021
Q2 		$8.4M Buy
478,600
+150,800
+46% +$3.43M 0.04% 494
2021
Q1 		$8.26M Buy
+327,800
New +$6.41M 0.04% 467
2018
Q3 		– Sell
-269,922
Closed -$5.39M – 979
2018
Q2 		$5.39M Sell
269,922
-460,452
-63% -$8.51M 0.02% 587
2018
Q1 		$12.8M Sell
730,374
-61,626
-8% -$1.31M 0.05% 373
2017
Q4 		$19.5M Sell
792,000
-100,298
-11% -$2.44M 0.08% 304
2017
Q3 		$23M Buy
892,298
+29,896
+3% +$801K 0.1% 234
2017
Q2 		$23.4M Buy
862,402
+402,486
+88% +$10.9M 0.13% 216
2017
Q1 		$13.7M Buy
+459,916
New +$13.3M 0.08% 327

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Point72 Asset Management's ACRS Position: Q1 2026 in Review

Point72 Asset Management sold out of Aclaris Therapeutics (ACRS) in Q1 2026, closing a stake of 87,175 shares — an estimated $262K sold.

Point72 Asset Management first reported a position in ACRS in Q1 2017 and held it in 18 quarters. The position peaked at $39.3M in Q1 2022. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Point72 Asset Management reported no remaining Aclaris Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 87,175 Aclaris Therapeutics shares in Q1 2026, an estimated $262K.
  • Point72 Asset Management first reported a position in Aclaris Therapeutics in Q1 2017 and held it in 18 quarters.
  • Point72 Asset Management's Aclaris Therapeutics position peaked at $39.3M in Q1 2022.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.